Skip to main content

Advertisement

Log in

The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review

  • Review Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Bleeding and thrombosis are long recognized complications of myelofibrosis (MF) and contribute significantly to its morbidity and mortality. However, so far, few studies have evaluated the frequency of these events, their characteristics, and their prognostic impact. Based on these studies, thrombotic events in MF are about as common as in essential thrombocytemia (ET) but less common than in polycythemia vera (PV), while bleeding events are relatively more common in MF than in ET or PV. The emergence of the concept of prefibrotic primary MF (PMF), which is associated with a higher frequency of thrombohemorrhagic complications than ET, and the growing evidence that prefibrotic PMF may also have a different thrombotic and bleeding risk profiles than fibrotic (overt) PMF have emphasized the need for a reappraisal of the risk of thrombosis and hemorrhage in patients with MF. In this review, we discuss the frequency of thrombosis and bleeding in patients with MF, including prefibrotic PMF and their established and potential risk factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405. doi:10.1182/blood-2016-03-643544

    Article  CAS  PubMed  Google Scholar 

  2. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, Dupriez B, Levine RL, Passamonti F, Gotlib J, Reilly JT, Vannucchi AM, Hanson CA, Solberg LA, Orazi A, Tefferi A, International Working Group for Myelofibrosis R, Treatment (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working Group for Myelofibrosis Research and Treatment. Leukemia 22(2):437–438. doi:10.1038/sj.leu.2404914

    Article  CAS  PubMed  Google Scholar 

  3. Castro-Malaspina H, Jhanwar SC (1984) Properties of myelofibrosis-derived fibroblasts. Prog Clin Biol Res 154:307–322

    CAS  PubMed  Google Scholar 

  4. Hasselbalch HC (2013) The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev 24(2):133–145. doi:10.1016/j.cytogfr.2013.01.004

    Article  CAS  PubMed  Google Scholar 

  5. Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S (2014) Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med 7:89–101. doi:10.2147/IJGM.S51800

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Cervantes F, Alvarez-Larran A, Arellano-Rodrigo E, Granell M, Domingo A, Montserrat E (2006) Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution. Leukemia 20(1):55–60. doi:10.1038/sj.leu.2404048

    Article  CAS  PubMed  Google Scholar 

  7. Wehmeier A, Daum I, Jamin H, Schneider W (1991) Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann Hematol 63(2):101–106

    Article  CAS  PubMed  Google Scholar 

  8. Rupoli S, Goteri G, Picardi P, Micucci G, Canafoglia L, Scortechini AR, Federici I, Giantomassi F, Da Lio L, Zizzi A, Honorati E, Leoni P (2015) Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis. Diagn Pathol 10:29. doi:10.1186/s13000-015-0269-1

    Article  PubMed  PubMed Central  Google Scholar 

  9. Kander EM, Raza S, Zhou Z, Gao J, Zakarija A, McMahon BJ, Stein BL (2015) Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort. Int J Hematol 102(5):587–593. doi:10.1007/s12185-015-1871-4

    Article  CAS  PubMed  Google Scholar 

  10. Thiele J, Imbert M, Pierre R, Vardiman JW, Brunning RD, Flandrin G (2001) Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) WHO classification of tumours: tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, p 35–38

  11. Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Gangat N, Rambaldi A, Tefferi A, Barbui T (2012) Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according 2008 WHO criteria. Leukemia 26(4):716–719. doi:10.1038/leu.2011.258

    Article  CAS  PubMed  Google Scholar 

  12. Kaifie A, Kirschner M, Wolf D, Maintz C, Hanel M, Gattermann N, Gokkurt E, Platzbecker U, Hollburg W, Gothert JR, Parmentier S, Lang F, Hansen R, Isfort S, Schmitt K, Jost E, Serve H, Ehninger G, Berdel WE, Brummendorf TH, Koschmieder S, Study Alliance L (2016) Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol 9:18. doi:10.1186/s13045-016-0242-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, Alvarez-Larran A, Rambaldi A, Finazzi G, Barosi G (2010) Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 115(4):778–782. doi:10.1182/blood-2009-08-238956

    Article  CAS  PubMed  Google Scholar 

  14. Elliott MA, Pardanani A, Lasho TL, Schwager SM, Tefferi A (2010) Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. Haematologica 95(10):1788–1791

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Buxhofer-Ausch V, Gisslinger H, Thiele J, Gisslinger B, Kvasnicka HM, Mullauer L, Frantal S, Carobbio A, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Finazzi G, Gangat N, Tefferi A, Barbui T (2012) Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients. Am J Hematol 87(7):669–672

    Article  PubMed  Google Scholar 

  16. Buxhofer-Ausch V, Gisslinger B, Schalling M, Gleiss A, Schiefer A-I, Müllauer L, Thiele J, Kralovics R, Gisslinger H (2016) Impact of white blood cell counts at diagnosis and during follow-up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis. Br J Haematol. doi:10.1111/bjh.14202

  17. Barosi G, Rosti V, Bonetti E, Campanelli R, Carolei A, Catarsi P, Isgro AM, Lupo L, Massa M, Poletto V, Viarengo G, Villani L, Magrini U (2012) Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PLoS One 7(4):e35631

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, d'Amore ES, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Antonioli E, Carrai V, Gisslinger H, Buxhofer-Ausch V, Mullauer L, Carobbio A, Gianatti A, Gangat N, Hanson CA, Tefferi A (2011) Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 29(23):3179–3184

    Article  PubMed  Google Scholar 

  19. Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Finazzi G, Gangat N, Tefferi A, Barbui T (2011) Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 117(22):5857–5859

    Article  CAS  PubMed  Google Scholar 

  20. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23(10):2224–2232

    Article  PubMed  Google Scholar 

  21. Hultcrantz M, Wilkes SR, Kristinsson SY, Andersson TM, Derolf AR, Eloranta S, Samuelsson J, Landgren O, Dickman PW, Lambert PC, Bjorkholm M (2015) Risk and cause of death in patients diagnosed with Myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study. J Clin Oncol 33(20):2288–2295

    Article  PubMed  Google Scholar 

  22. Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW (2012) Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 120(25):4921–4928

    Article  CAS  PubMed  Google Scholar 

  23. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F (2006) Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 91(2):169–175

    CAS  PubMed  Google Scholar 

  24. Jensen MK, de Nully BP, Lund BV, Nielsen OJ, Hasselbalch HC (2001) Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol 66(3):143–151

    Article  CAS  PubMed  Google Scholar 

  25. Alvarez-Larran A, Arellano-Rodrigo E, Reverter JC, Domingo A, Villamor N, Colomer D, Cervantes F (2008) Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. Ann Hematol 87(4):269–276. doi:10.1007/s00277-007-0386-3

    Article  CAS  PubMed  Google Scholar 

  26. Kirchhofer D, Riederer MA, Baumgartner HR (1997) Specific accumulation of circulating monocytes and polymorphonuclear leukocytes on platelet thrombi in a vascular injury model. Blood 89(4):1270–1278

    CAS  PubMed  Google Scholar 

  27. Kuijper PH, Gallardo Torres HI, Lammers JW, Sixma JJ, Koenderman L, Zwaginga JJ (1997) Platelet and fibrin deposition at the damaged vessel wall: cooperative substrates for neutrophil adhesion under flow conditions. Blood 89(1):166–175

    CAS  PubMed  Google Scholar 

  28. Leoni P, Rupoli S, Lai G, Brunelli MA, Belmonte MM, Pugnaloni A, Rabini RA, Mazzanti L, Biagini G (1994) Platelet abnormalities in idiopathic myelofibrosis: functional, biochemical and immunomorphological correlations. Haematologica 79(1):29–39

    CAS  PubMed  Google Scholar 

  29. Hobbs CM, Manning H, Bennett C, Vasquez L, Severin S, Brain L, Mazharian A, Guerrero JA, Li J, Soranzo N, Green AR, Watson SP, Ghevaert C (2013) JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood 122(23):3787–3797

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Finazzi MC, Carobbio A, Cervantes F, Isola IM, Vannucchi AM, Guglielmelli P, Rambaldi A, Finazzi G, Barosi G, Barbui T (2015) CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis. Leukemia 29(5):1209–1210. doi:10.1038/leu.2014.343

    Article  CAS  PubMed  Google Scholar 

  31. Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Buller HR, Cattaneo M (2009) Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res 124(4):409–417

    Article  CAS  PubMed  Google Scholar 

  32. Pei Y-Q, Wu Y, Wang F, Cui W (2016) Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis. Ann Hematol 95(9):1391–1398

    Article  CAS  PubMed  Google Scholar 

  33. Papadakis E, Papageorgiou V, Tsepanis K, Theocharidou D, Papadopoulos VK, Georgiou E, Efraimidou S, Kioumi A (2012) Impact of inherited thrombophilia factors on thrombotic risk in patients with newly diagnosed BCR- Abl (−) myeloproliferative disorders; finally a role of MTHFR- C677T polymorphism? Blood 120(21):5065

  34. Tevet M, Ionescu R, Dragan C, Lupu AR (2015) Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with Myeloproliferative disorders. Maedica (Buchar) 10(1):27–32

    Google Scholar 

  35. El Accaoui RN, Shamseddeen WA, Taher AT (2007) Thalidomide and thrombosis. A meta-analysis. Thromb Haemost 97(6):1031–1036

    PubMed  Google Scholar 

  36. Knight R, DeLap RJ, Zeldis JB (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354(19):2079–2080

    Article  CAS  PubMed  Google Scholar 

  37. Barbui T, Finazzi G (2006) Myeloproliferative disease in pregnancy and other management issues. Hematology (am Soc Hematol Educ program):246–252. doi:10.1182/asheducation-2006.1.246

  38. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kroger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A, European L (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29(6):761–770

    Article  PubMed  PubMed Central  Google Scholar 

  39. Vannucchi AM (2011) Management of myelofibrosis. Hematol Am Soc Hematol Educ Program 2011:222–230. doi:10.1182/asheducation-2011.1.222

    Google Scholar 

  40. Visani G, Finelli C, Castelli U, Petti MC, Ricci P, Vianelli N, Gianni L, Zuffa E, Aloe Spiriti MA, Latagliata R (1990) Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 75(1):4–9

    Article  CAS  PubMed  Google Scholar 

  41. Hasselbalch H (1990) Idiopathic myelofibrosis: a clinical study of 80 patients. Am J Hematol 34(4):291–300

    Article  CAS  PubMed  Google Scholar 

  42. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A (2009) New prognostic scoring system for primary myelofibrosis based on a study of the international working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895–2901. doi:10.1182/blood-2008-07-170449

    Article  CAS  PubMed  Google Scholar 

  43. Didisheim P, Bunting D (1966) Abnormal platelet function in myelofibrosis. Am J Clin Pathol 45(5):566–573

    Article  CAS  PubMed  Google Scholar 

  44. Ashrani AA, Tefferi A, Pruthi RK, Pardanani A (2015) Acquired factor V deficiency in myeloproliferative neoplasms: a Mayo Clinic series of 33 patients. Br J Haematol 171(5):875–879

    Article  PubMed  Google Scholar 

  45. Sanchez-Luceros A, Meschengieser SS, Woods AI, Blanco AN, Kempfer AC, Casais P, Salviu MJ, Lazzari MA (2002) Acquired von Willebrand factor abnormalities in myeloproliferative disorders and other hematologic diseases: a retrospective analysis by a single institution. Haematologica 87(3):264–270

    CAS  PubMed  Google Scholar 

  46. Landolfi R, Marchioli R, Patrono C (1997) Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Thromb Haemost 78(1):617–621

    CAS  PubMed  Google Scholar 

  47. Dubois A, Dauzat M, Pignodel C, Pomier-Layrargues G, Marty-Double C, Lopez FM, Janbon C (1993) Portal hypertension in lymphoproliferative and myeloproliferative disorders: hemodynamic and histological correlations. Hepatology 17(2):246–250

    Article  CAS  PubMed  Google Scholar 

  48. Denninger MH, Chait Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, Erlinger S, Briere J, Valla D (2000) Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 31(3):587–591. doi:10.1002/hep.510310307

    Article  CAS  PubMed  Google Scholar 

  49. Huang J, Tefferi A (2009) Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol 83(2):154–155

    Article  CAS  PubMed  Google Scholar 

  50. Besa EC, Nowell PC, Geller NL, Gardner FH (1982) Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Cancer 49(2):308–313

    Article  CAS  PubMed  Google Scholar 

  51. Cervantes F, Alvarez-Larran A, Domingo A, Arellano-Rodrigo E, Montserrat E (2005) Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 129(6):771–775

    Article  CAS  PubMed  Google Scholar 

  52. Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, Wiseman G, Gray LA, Schroeder G, Reeder T, Zeldis JB, Tefferi A (2003) A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 101(7):2534–2541. doi:10.1182/blood-2002-09-2928

    Article  CAS  PubMed  Google Scholar 

  53. Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM (2006) Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 108(4):1158–1164. doi:10.1182/blood-2006-02-004572

    Article  CAS  PubMed  Google Scholar 

  54. Boddu P, Falchi L, Hosing C, Newberry K, Bose P, Verstovsek S (2017) The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: a case-based review. Leuk Res 58:14–22. doi:10.1016/j.leukres.2017.03.008

    Article  PubMed  Google Scholar 

  55. Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH (2016) Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing Committee of the American Society for apheresis: the seventh special issue. J Clin Apheresis 31(3):149–162

    PubMed  Google Scholar 

  56. Campbell PJ, Bareford D, Erber WN, Wilkins BS, Wright P, Buck G, Wheatley K, Harrison CN, Green AR (2009) Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol 27(18):2991–2999

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Palandri F, Polverelli N, Catani L, Sollazzo D, Ottaviani E, Parisi S, Baccarani M, Vianelli N (2012) Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients. Br J Haematol 156(2):281–284

    Article  CAS  PubMed  Google Scholar 

  58. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A (2012) Development and validation of an international prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 120(26):5128–5133 quiz 5252

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

DKC and SV provided the concept and design of the study, wrote the manuscript, and provided final review and approval. LF helped in revising the article and providing final review and approval.

Corresponding author

Correspondence to Srdan Verstovsek.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

KC, D., Falchi, L. & Verstovsek, S. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review. Ann Hematol 96, 1595–1604 (2017). https://doi.org/10.1007/s00277-017-3099-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-017-3099-2

Keywords

Navigation